Cellebrite (CLBT) CPO discloses sizable holdings in shares, RSUs, PSUs and options

Rhea-AI Filing Summary

Cellebrite DI Ltd. Chief People Officer Tadmor-Eilat Zohar reported initial beneficial ownership of the company’s equity. She holds 129,814 Ordinary Shares directly, including multiple blocks of restricted share units and performance share units that vest over time based on service and performance conditions.

She also holds stock options over 22,722 Ordinary Shares at an exercise price of $4.95 per share expiring on February 13, 2033, and options over 28,236 Ordinary Shares at an exercise price of $11.51 per share expiring on March 19, 2034.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tadmor-Eilat Zohar

(Last) (First) (Middle)

94 SHLOMO SHMELZER ROAD

(Street)

PETAH TIKVA 4970602

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Cellebrite DI Ltd. [ CLBT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares, par value NIS 0.00001 ("Ordinary Shares")	129,814(1)(2)(3)(4)(5)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options	(6)	02/13/2033	Ordinary Shares	22,722	$4.95	D
Stock options	(7)	03/19/2034	Ordinary Shares	28,236	$11.51	D

Explanation of Responses:

1. Includes 21,988 Ordinary Shares that are represented by restricted share units ("RSUs") that were granted on February 14, 2023, of which 5,497 vest on each of May 14, 2026 and every three months thereafter through February 14, 2027. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer upon settlement.

2. Includes 15,615 Ordinary Shares that are represented by RSUs that were granted on March 20, 2024, of which 1,735 vest on each of March 20, 2026 and every three months thereafter through March 20, 2028.

3. Includes 11,760 Ordinary Shares that are represented by RSUs that were granted on February 11, 2025, of which 980 vest on each of May 11, 2026 and every three months thereafter through February 11, 2029.

4. Includes 3,471 Ordinary Shares that are represented by performance share units ("PSUs") that were granted on March 20, 2024, and vest based on the Issuer meeting certain total shareholder return thresholds for 60 consecutive trading days through March 20, 2028. Each PSU represents a contingent right to receive one Ordinary Share of the Issuer upon vesting and settlement.

5. Includes 39,491 Ordinary Shares that are represented by RSUs that were granted on February 10, 2026 and vest as follows: 9,875 vest on the first anniversary of the grant date and 2,468 vest every three months thereafter through February 10, 2030.

6. Of these stock options, 7,574 are fully vested and exercisable and 3,787 vest on each of May 14, 2026 and every three months thereafter through February 14, 2027.

7. Of these stock options, 12,360 are fully vested and exercisable and 1,764 vest on each of March 20, 2026 and every three months thereafter through March 20, 2028.

	/s/ Zohar Tadmor-Eilat	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Cellebrite (CLBT) Form 3 filing by Tadmor-Eilat Zohar show?

The Form 3 shows Chief People Officer Tadmor-Eilat Zohar’s initial equity stake, including 129,814 Ordinary Shares and multiple blocks of RSUs and PSUs that vest over several years, plus stock options over 50,958 underlying Ordinary Shares at fixed exercise prices.

How many Ordinary Shares does Cellebrite (CLBT) CPO Tadmor-Eilat Zohar beneficially own?

She beneficially owns 129,814 Ordinary Shares directly. This total includes time-based restricted share units granted between 2023 and 2026 and performance share units that vest only if specified total shareholder return thresholds are achieved over a defined performance period.

What stock options does Cellebrite (CLBT) CPO Tadmor-Eilat Zohar hold according to the Form 3?

She holds stock options over 22,722 Ordinary Shares with a $4.95 exercise price expiring February 13, 2033, and options over 28,236 Ordinary Shares with an $11.51 exercise price expiring March 19, 2034, combining fully vested and future-vesting tranches.

How do Tadmor-Eilat Zohar’s RSUs in Cellebrite (CLBT) vest over time?

Her RSUs granted in 2023, 2024, 2025, and 2026 vest in quarterly installments after initial anniversaries, with specific share amounts vesting every three months through dates ranging from February 14, 2027 to February 10, 2030, subject to continued service.

What performance share units (PSUs) does Cellebrite (CLBT) disclose for Tadmor-Eilat Zohar?

She holds 3,471 PSUs granted March 20, 2024. These vest only if Cellebrite meets specified total shareholder return thresholds for 60 consecutive trading days through March 20, 2028, each PSU representing a contingent right to one Ordinary Share upon vesting and settlement.

Are Tadmor-Eilat Zohar’s Cellebrite (CLBT) stock options already fully vested?

Only part of her options are fully vested. For the lower-priced grant, 7,574 options are vested, with additional tranches vesting quarterly through February 14, 2027. For the higher-priced grant, 12,360 options are vested, with remaining options vesting quarterly through March 20, 2028.